clinical trial

[Harpoon Therapeutics, Inc.] Harpoon Therapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation for HPN328, a delta like ligand 3- targeting TriTAC®, for the treatment of SCLC.

[Harpoon Therapeutics, Inc.] Harpoon Therapeutics, Inc. announced that the US FDA has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC®, for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four lines of therapy.

[Stem Cell Research & Therapy] A prospective randomized double-blind placebo-controlled clinical trial assessed the safety and efficacy of secretome derived from allogeneic menstrual blood stromal cells as a treatment in patients with severe COVID-19.

[Fulcrum Therapeutics, Inc.] Fulcrum Therapeutics, Inc. announced its plans to initiate REACH, a Phase III clinical trial of losmapimod in people with facioscapulohumeral muscular dystrophy, in the second quarter of 2022.

[Evaxion Biotech A/S] Evaxion Biotech A/S finalized recruitment for Phase I/IIa clinical trial of EVX-02 in adjuvant melanoma patients.

[DURECT Corporation] DURECT Corporation announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase IIb study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis. patients.